AstraZeneca’s rare blood disorder pill approved in Japan

As­traZeneca’s add-on pill for the rare blood dis­or­der parox­ys­mal noc­tur­nal he­mo­glo­bin­uria (PNH) won its first ap­proval in Japan, the com­pa­ny an­nounced Fri­day.

The drug, an oral fac­tor D in­hibitor called dan­i­co­pan, is “un­der re­view with mul­ti­ple glob­al health au­thor­i­ties,” a spokesper­son told End­points News. The com­pa­ny de­clined to com­ment on a time­line for po­ten­tial ap­proval in the US. Dan­i­co­pan will be sold un­der the brand name Voydeya in Japan for pa­tients who have had an in­suf­fi­cient re­sponse from C5 in­hibitors, the cur­rent stan­dard of care.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.